Ascendis Pharma A/S (ASND) vs BioMarin Pharmaceutical (BMRN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Ascendis Pharma A/S (ASND) has outperformed BioMarin Pharmaceutical (BMRN) over the past year, gaining 8.8% versus a gain of 0.9%. Over five years, ASND leads with a +42.8% price change compared with -27.3% for BMRN. Ascendis Pharma A/S is the larger company by market cap ($14.75 billion vs $10.48 billion), about 1.4 times the size.
On valuation, BioMarin Pharmaceutical trades at a lower forward P/E (8.2x vs 20.7x for Ascendis Pharma A/S).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASND | BMRN |
|---|---|---|
| Share price | $224.09 | $54.13 |
| Market cap | $14.75B | $10.48B |
| 1-day change | -1.89% | -1.95% |
| YTD return | +7.11% | -7.12% |
| 1-year return | +8.84% | +0.91% |
| 5-year return | +42.77% | -27.26% |
| P/E ratio (TTM) | 17.17 | 146.28 |
| Forward P/E | 20.71 | 8.16 |
| EPS (TTM) | $13.05 | $0.37 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $3.22B |
| Revenue growth (YoY) | — | +12.87% |
| Net income (latest FY) | — | $348.90M |
| Gross margin | — | 77.73% |
| Operating margin | — | 12.71% |
| Net margin | — | 10.83% |
| 52-week high | $282.15 | $70.98 |
| 52-week low | $186.05 | $49.26 |
| Distance from 52-week high | -20.58% | -23.75% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +36.48% | +69.27% |
| Average volume | 658.78K | 2.01M |
| Shares outstanding | 65.80M | 193.57M |
| Employees | 1,189 | 3,221 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BioMarin Pharmaceutical trades at a higher earnings multiple (146.3x vs 17.2x trailing P/E).
About Ascendis Pharma A/S
ASND stock →Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,189 employees
About BioMarin Pharmaceutical
BMRN stock →BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations.
Health Care · Biotechnology: Pharmaceutical Preparations · 3,221 employees
ASND vs BMRN FAQ
Which is bigger, Ascendis Pharma A/S or BioMarin Pharmaceutical?
Ascendis Pharma A/S (ASND) is larger, with a market capitalization of $14.75B compared with $10.48B for BioMarin Pharmaceutical (BMRN).
Which stock has performed better over the past year, ASND or BMRN?
ASND returned +8.84% over the past 12 months, compared with +0.91% for BMRN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ASND or BMRN?
ASND has the lower trailing P/E at 17.2, versus 146.3 for BMRN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Ascendis Pharma A/S and BioMarin Pharmaceutical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.